Table 2.

Comparison of the two G-CSF arms

		G-CSF treatment group		p-value
		5μg/kg/day	10μg/kg/day
Days of G-CSF treatment a
DAV1	N	23	23	0.86
	Median (range)	13 (6–26)	14 (6–30)
DAV2	N	18	18	0.57
	Median (range)	15 (10–33)	14 (8–29)
Days of neutropenia b
DAV1	Median (range)	13 (6–27)	12 (6–29)	0.54
DAV2	Median (range)	11 (4–25)	10 (5–27)
Days of hospitalization b
DAV1	Median (range)	0 (0–18)	0 (0–25)	0.48
DAV2	Median (range)	2 (0–23)	0 (0–22)
Adverse events, antimicrobials, transfusions c		Cumulative mean function estimate at last event (95% confidence interval)
Febrile neutropenia (episodes)		1.91 (1.35–2.71)	1.60 (1.22–2.09)	0.37
Grade 2-4 infection (episodes)		1.10 (0.60–2.02)	1.43 (0.77–2.63)	0.48
Antibiotic therapy (episodes)		4.27 (3.15–5.79)	4.55 (3.52–5.88)	0.72
IV antibiotic therapy (episodes)		3.30 (2.49–4.39)	4.02 (2.95–5.46)	0.27
Antifungal therapy (episodes)		2.48 (1.69–3.64)	1.80 (1.20–2.68)	0.20
Red blood cell transfusion (number)		7.08 (5.55–9.04)	7.05 (5.48–9.06)	0.98
Platelet transfusion (number)		10.21 (6.74–15.49)	10.48 (7.39–14.87)	0.98
Supportive care costs b		Median (range) $U.S.
Antimicrobials		1462 (92–14779)	1249 (14–2689)	0.61
Laboratory tests		7335 (852–14853)	7319 (1280–12916)	0.90
Diagnostic imaging		420 (113–3549)	902.24 (117–4660)	0.16
Room/procedure		5009 (582–15712)	3974 (399–7864)	0.21
Transfusion		2693 (1071–6678)	2098 (446–5433)	0.19
Other support		2690 (170–9068)	3059 (160–10082)	0.97
Total		18648 (1434–60040)	19108 (6014–33119)	0.99

^aWilcoxon rank-sum test

^bRepeated-measures mixed-effects model

^c Proportional means model

Abbreviations: G-CSF, granulocyte colony-stimulating factor; DAV, daunorubicin, cytarabine and etoposide; IV, intravenous